Contact
Please use this form to send email to PR contact of this press release:
TiGenix announces six-month Phase I/II results of AlloCSC-01 in Acute Myocardial Infarction
TO:
Please use this form to send email to PR contact of this press release:
TiGenix announces six-month Phase I/II results of AlloCSC-01 in Acute Myocardial Infarction
TO: